Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single Center, First-In-Man, Proof-of-Concept Study: Transplantation of Uncontrolled DCD Kidneys REconditioned by a Novel Ex-VIVo Perfusion MEthod - The REVIVEME Trial

NCT05703633 is registered in ClinicalTrials.gov with Sahlgrenska University Hospital as lead sponsor.

NCT NCT05703633
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05703633 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single Center, First-In-Man, Proof-of-Concept Study: Transplantation of Uncontrolled DCD Kidneys REconditioned by a Novel Ex-VIVo Perfusion MEthod - The REVIVEME Trial
Lead sponsor
Sahlgrenska University Hospital
Phase
Phase 1/2
Overall status
Unknown status
Start date
August 21, 2023
Completion date
December 31, 2024
Enrollment
8 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

end-stage kidney disease